Clinical Utility of Advanced Microbiology Testing Tools - PubMed (original) (raw)

Review

. 2019 Aug 26;57(9):e00495-19.

doi: 10.1128/JCM.00495-19. Print 2019 Sep.

Faranak Atrzadeh 2, C A Burnham 3, Stephen Cavalieri 4, James Dunn 5, Stephen Jones 6, Charles Mathews 7, Peggy McNult 8, John Meduri 9, Chris Newhouse 10, Duane Newton 11, Michael Oberholzer 12, John Osiecki 10, David Pedersen 6, Nicole Sweeney 13, Natalie Whitfield 14, Joe Campos; ASM Clinical and Public Health Microbiology Committee and the ASM Corporate Council

Affiliations

Review

Clinical Utility of Advanced Microbiology Testing Tools

Melissa B Miller et al. J Clin Microbiol. 2019.

Abstract

Advanced microbiology technologies are rapidly changing our ability to diagnose infections, improve patient care, and enhance clinical workflow. These tools are increasing the breadth, depth, and speed of diagnostic data generated per patient, and testing is being moved closer to the patient through rapid diagnostic technologies, including point-of-care (POC) technologies. While select stakeholders have an appreciation of the value/importance of improvements in the microbial diagnostic field, there remains a disconnect between clinicians and some payers and hospital administrators in terms of understanding the potential clinical utility of these novel technologies. Therefore, a key challenge for the clinical microbiology community is to clearly articulate the value proposition of these technologies to encourage payers to cover and hospitals to adopt advanced microbiology tests. Specific guidance on how to define and demonstrate clinical utility would be valuable. Addressing this challenge will require alignment on this topic, not just by microbiologists but also by primary care and emergency room (ER) physicians, infectious disease specialists, pharmacists, hospital administrators, and government entities with an interest in public health. In this article, we discuss how to best conduct clinical studies to demonstrate and communicate clinical utility to payers and to set reasonable expectations for what diagnostic manufacturers should be required to demonstrate to support reimbursement from commercial payers and utilization by hospital systems.

Keywords: clinical utility; evidence; health economics; molecular methods; outcomes research; reimbursement.

Copyright © 2019 Miller et al.

PubMed Disclaimer

Figures

FIG 1

FIG 1

Endpoints for studies of clinical utility.

FIG 2

FIG 2

Select examples of types of trials that can be used to demonstrate clinical utility.

Similar articles

Cited by

References

    1. Sousa AM, Pereira MO. 2013. A prospect of current microbial diagnosis methods, p 1429–1438. In Mendez-Vilas A. (ed), Microbial pathogens and strategies for combating them: science, technology and education, vol 3 Formatex, Bajadoz, Spain.
    1. Van Belkum A, Durand G, Peyret M, Chatellier S, Zambardi G, Schrenzel J, Shortridge D, Engelhardt A, Dunne WM. 2013. Rapid clinical bacteriology and its future impact. Ann Lab Med 33:14–27. doi:10.3343/alm.2013.33.1.14. - DOI - PMC - PubMed
    1. Lazcka O, Del Campo FJ, Muñoz FX. 2007. Pathogen detection: a perspective of traditional methods and biosensors. Biosens Bioelectron 22:1205–1217. doi:10.1016/j.bios.2006.06.036. - DOI - PubMed
    1. Freeman K, Mistry H, Tsertsvadze A, Royle P, McCarthy N, Taylor-Phillips S, Manuel R, Mason J. 2017. Multiplex tests to identify gastrointestinal bacteria, viruses and parasites in people with suspected infectious gastroenteritis: a systematic review and economic analysis. Health Technol Assess 21. doi:10.3310/hta21230. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. 2017. Antibiotic use in the United States, 2017: progress and opportunities. Centers for Disease Control and Prevention, Atlanta, GA.

Publication types

MeSH terms

LinkOut - more resources